Patrick Schöffski

Rega Institute for Medical Research — Belgium

Medicine · Health Sciences

92h-index43.2kcitations1.1kworks5.12yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Gastrointestinal Tumor Research and Treatment(412), Sarcoma Diagnosis and Treatment(365), Gastric Cancer Management and Outcomes(165), Renal cell carcinoma treatment(80), Cancer Genomics and Diagnostics(73)

Publications1.1k total

Figure 2 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
2025Open Access
Data from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
2025Open Access
Table S1 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
2025Open Access
Table 1 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
2025Open Access
Table S2 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
2025Open Access
Table S5 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
2025Open Access
Figure S1 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
2025Open Access
Table 3 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
2025Open Access
Table 4 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
2025Open Access
Figure S3 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
2025Open Access
Figure S2 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
2025Open Access
Table 2 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
2025Open Access
Table S4 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
2025Open Access
Table S7 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
2025Open Access
Table S3 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
2025Open Access
Table S6 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
2025Open Access
Figure 1 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
2025Open Access
Figure S2 from Results of an Open-label, Phase Ia/b Study of Pembrolizumab plus Olaratumab in Patients with Unresectable, Locally Advanced, or Metastatic Soft-Tissue Sarcoma
2025Open Access
Supplementary Data Table 6 from Bolus versus Continuous Intravenous Delivery of Doxorubicin in Soft-Tissue Sarcomas: <i>Post Hoc</i> Analysis of a Prospective Randomized Trial (SARC021/TH CR-406)
2025Open Access
Table S3 from Results of an Open-label, Phase Ia/b Study of Pembrolizumab plus Olaratumab in Patients with Unresectable, Locally Advanced, or Metastatic Soft-Tissue Sarcoma
2025Open Access
page 1 of 57Next →

Frequent Co-authors

Jean‐Yves Blay(21), Piotr Rutkowski(19), Peter Hohenberger(17), Hans Gelderblom(16), Sebastian Bauer(15), Robin L. Jones(15), Paolo G. Casali(14), Peter Reichardt(13), Giovanni Grignani(12), Silvia Stacchiotti(12), Angelo Paolo Dei Tos(11), Javier Martín‐Broto(11), Alessandro Gronchi(11), Stefan Sleijfer(11), Winette T.A. van der Graaf(10), Ian Judson(10), Sylvie Bonvalot(10), Xavier García del Muro(10), Heikki Joensuu(10), Bernd Kasper(10)